Needham downgraded Haemonetics from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2025 | Buy → Hold | Needham | |
| 12/11/2025 | $88.00 | Buy → Neutral | Citigroup |
| 8/11/2025 | $78.00 | Strong Buy → Outperform | Raymond James |
| 8/8/2025 | $62.00 | Overweight → Neutral | Analyst |
| 8/8/2025 | $95.00 → $86.00 | Outperform | Barrington Research |
| 7/9/2025 | $90.00 | Neutral → Buy | Citigroup |
| 6/26/2025 | $87.00 | Outperform | Robert W. Baird |
| 2/7/2025 | $95.00 → $68.00 | Neutral → Underperform | BofA Securities |
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation. The 510(k) clearance was supported by clinical
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N. A replay of the recorded webcast will become accessible 12 hours after the event and will be a
Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registra
8-K - HAEMONETICS CORP (0000313143) (Filer)
10-Q - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
Needham downgraded Haemonetics from Buy to Hold
Citigroup downgraded Haemonetics from Buy to Neutral and set a new price target of $88.00
Raymond James downgraded Haemonetics from Strong Buy to Outperform and set a new price target of $78.00
Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registra
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structu
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026. The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the cal
SC 13G - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the